2021-07-29| Asia-Pacific

Japan’s Chugai Infuses $500 Million for a New API Manufacturing Building

by Tyler Chen
Share To

With nearly $500 million (55.5 billion yen) investment, Japan’s Chugai Pharmaceutical adds another manufacturing building to produce active pharmaceutical ingredients (APIs) for small and mid-size molecule drugs. This is the third building Chugai established for this drug type.


FJ3 to Support Clinical Trials to Market Launch

The building, also known as FJ3, will be located in the Fujieda Plant along with FJ1 and FJ2 and is expected to go into full operation in March 2025.

“FJ3 will be a world-class production facility with advanced production technologies and automate manufacturing operations which enable labor-saving and productivity improvements, as well as thoroughly considering environment and safety,” said Osamu Okuda, President, and CEO of Chugai.

FJ3 will be a five-story isolated building and installed API production lines with advanced containment technologies to meet the manufacturing needs as more candidates are about to enter clinical trials. The facility will produce high potency API from early clinical trials to market launches.

The construction of FJ3 will begin in 2022 and finish in February 2024. Currently, FJ2 is still under construction and will be completed in 2022.

The mid-size molecule is Chugai’s third modality, following small molecules and antibodies. With the expectation of mid-size molecule drugs being the driving force for the firm’s medium to long-term growth, Chugai has established two buildings for production in 2019 and 2021.

Related Article: Chugai Initiates Actemra’s Phase 3 COVID-19 Trials in Japan

© All rights reserved. Collaborate with us:
Related Post
Japan’s Gaia BioMedicine Teams Up With TreeFrog Therapeutics To Advance NK-Like Cell Therapies
AstraZeneca Welcomes Neurofibromatosis And Asthma Treatment Approvals in Japan
Daiichi Sankyo Wins Approval For Cancer Treatment in Japan
GSK Bets $593 Million To License Scynexis’ Oral Antifungal
3D Printed Brain Model Could Aid in Neurosurgery
Latest Study on Neuronal Gene Expression May Shed Light on the Memory Formation Process
Emergent BioSolutions’ Over-The-Counter Naloxone Nasal Spray Receives FDA Greenlight
Current Trends of iPSC Manufacturing and Clinical Applications – An Interview with Professor Xianmin Zeng
U.S.-German Joint Discovery May Spark Breakthrough in Diabetes Research
Merck Regains Worldwide Rights to BAVENCIO After Parting Ways with Pfizer
Scroll to Top